钠-葡萄糖协同转运体2抑制剂改善糖尿病患者心血管疾病预后机制的研究进展

Mechanism Research Progress of Sodium-glucose Cotransporter 2 Inhibitors in Improving the Prognosis of Cardiovascular Diseases in Diabetic Patients

钠-葡萄糖协同转运体2(SGLT2)抑制剂虽然已广泛应用于糖尿病、心脏病、肾脏病等疾病的治疗,但其具体的作用机制并不完全明确。本文以SGLT2抑制剂作用于自主神经系统的病理生理机制为背景,从心血管自主神经角度对相关基础研究和临床研究进行综述,发现SGLT2抑制剂可通过调节自主神经功能改善糖尿病患者心血管疾病预后,而这种作用机制可能是通过中枢神经系统介导的。

Although sodium glucose cotransporter 2(SGLT2)inhibitors have been widely used in diabetes,cardiology and nephrology,but the specific mechanisms are still poorly understood.Based on the pathophysiological mechanism of SGLT2 inhibitors acting on autonomic nervous system,this review summarizes the relevant basic research and clinical research from the perspective of cardiovascular autonomic nervous,and finds that SGLT2 inhibitors improves the prognosis of cardiovascular disease in diabetic patients by regulating the function of autonomic nervous,and this mechanism may be mediated by central nervous system.